Friday, January 18, 2019 9:55:24 AM
I would like to see them sell their CASI stock as soon as they can. Makes no sense to me that a small biotech holds stock in another small biotech, especially since we are now disinterested in their drugs.
I would like to see a filing for Rolontis approval in Europe and a follow on co-licensing deal for Europe.
I still think JT may be making a mistake with Qapzola. Looks like they are not making any efforts to push the recruiting through. I believe Qapzola is a $100M+ product and they should get it approved and co-license it. This is a bird in hand.
I want them to find another late stage portfolio complimenting drug, but think they need to get Rolontis selling or the PPS up substantially before they can afford a new late stage drug. Perhaps in late 2020.
SPPI is now positioned to go it alone. We don't need to accept any low ball BO.
Fun times and a new beginning.
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM